Passage Bio, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ

25 Jun 2026

PASG

SCHEDULE: Baselake Partners Discloses 7.3% Stake in Passage Bio

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed a Schedule 13G reporting a 7.3% beneficial ownership stake in Passage Bio, Inc.

NASDAQ

14 Nov 2025

PASG

Passage Bio, INC

SCHEDULE: Lynx1 Capital Boosts Stake in Passage BIO to 19.6%

Lynx1 Capital Management LP and Weston Nichols have disclosed a significant beneficial ownership stake of 19.6% in Passage BIO, Inc., holding 623,704 shares.

NASDAQ

14 Feb 2025

PASG

Passage Bio, INC

SCHEDULE 13G/A: Lynx1 Capital Management and Weston Nichols Disclose 15% Stake in Passage BIO, Inc.

Lynx1 Capital Management LP and Weston Nichols have reported a 15.0% beneficial ownership stake in Passage BIO, Inc., holding 9,256,953 shares of common stock as of December 31, 2024.